Cytokinetics Inc (CYTK)

$65.12

-1.7

(-2.54%)▲

Live

Insights on Cytokinetics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 378.0K → 1.67M (in $), with an average increase of 77.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -128.63M → -136.89M (in $), with an average decrease of 3.2% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 88.5%

Performance

  • $64.11
    $65.33
    $65.12
    downward going graph

    1.55%

    Downside

    Day's Volatility :1.87%

    Upside

    0.32%

    downward going graph
  • $25.98
    $110.25
    $65.12
    downward going graph

    60.1%

    Downside

    52 Weeks Volatility :76.44%

    Upside

    40.93%

    downward going graph

Returns

PeriodCytokinetics IncSector (Health Care)Index (Russel 2000)
3 Months
-19.41%
1.7%
0.0%
6 Months
105.03%
11.3%
0.0%
1 Year
76.49%
5.4%
1.3%
3 Years
147.57%
13.9%
-22.1%

Highlights

Market Capitalization
6.9B
Book Value
- $3.8
Earnings Per Share (EPS)
-5.45
PEG Ratio
-0.42
Wall Street Target Price
95.06
Profit Margin
0.0%
Operating Margin TTM
-7620.69%
Return On Assets TTM
-33.73%
Return On Equity TTM
-572.15%
Revenue TTM
7.5M
Revenue Per Share TTM
0.08
Quarterly Revenue Growth YOY
-14.6%
Gross Profit TTM
-146.2M
EBITDA
-484.3M
Diluted Eps TTM
-5.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.45
EPS Estimate Next Year
-3.29
EPS Estimate Current Quarter
-0.97
EPS Estimate Next Quarter
-1.0

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Cytokinetics Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
20
19
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 45.98%

Current $65.12
Target $95.06

Company Financials

FY18Y/Y Change
Revenue
31.5M
↑ 135.64%
Net Income
-106.3M
↓ 16.83%
Net Profit Margin
-337.41%
↑ 618.53%
FY19Y/Y Change
Revenue
26.9M
↓ 14.71%
Net Income
-149.1M
↑ 40.23%
Net Profit Margin
-554.76%
↓ 217.35%
FY20Y/Y Change
Revenue
55.8M
↑ 107.79%
Net Income
-164.1M
↑ 10.12%
Net Profit Margin
-294.0%
↑ 260.76%
FY21Y/Y Change
Revenue
70.4M
↑ 26.15%
Net Income
-242.4M
↑ 47.67%
Net Profit Margin
-344.14%
↓ 50.14%
FY22Y/Y Change
Revenue
94.6M
↑ 34.3%
Net Income
-402.6M
↑ 66.09%
Net Profit Margin
-425.58%
↓ 81.44%
FY23Y/Y Change
Revenue
7.5M
↓ 92.04%
Net Income
-526.2M
↑ 30.73%
Net Profit Margin
-7.0K%
↓ 6563.05%
Q3 FY22Q/Q Change
Revenue
2.5M
↓ 97.17%
Net Income
-176.2M
↑ 512.46%
Net Profit Margin
-7.0K%
↓ 6972.8%
Q4 FY22Q/Q Change
Revenue
2.0M
↓ 22.19%
Net Income
-131.5M
↓ 25.38%
Net Profit Margin
-6.7K%
↑ 287.65%
Q1 FY23Q/Q Change
Revenue
4.6M
↑ 135.72%
Net Income
-129.4M
↓ 1.54%
Net Profit Margin
-2.8K%
↑ 3911.48%
Q2 FY23Q/Q Change
Revenue
867.0K
↓ 81.21%
Net Income
-128.6M
↓ 0.62%
Net Profit Margin
-14.8K%
↓ 12031.02%
Q3 FY23Q/Q Change
Revenue
378.0K
↓ 56.4%
Net Income
-129.4M
↑ 0.61%
Net Profit Margin
-34.2K%
↓ 19401.6%
Q4 FY23Q/Q Change
Revenue
1.7M
↑ 342.33%
Net Income
-136.9M
↑ 5.77%
Net Profit Margin
-8.2K%
↑ 26051.06%
FY18Y/Y Change
Total Assets
211.2M
↓ 28.37%
Total Liabilities
185.2M
↑ 0.15%
FY19Y/Y Change
Total Assets
289.8M
↑ 37.24%
Total Liabilities
300.8M
↑ 62.35%
FY20Y/Y Change
Total Assets
533.8M
↑ 84.19%
Total Liabilities
420.4M
↑ 39.79%
FY21Y/Y Change
Total Assets
841.3M
↑ 57.61%
Total Liabilities
597.5M
↑ 42.11%
FY22Y/Y Change
Total Assets
1.0B
↑ 20.62%
Total Liabilities
1.1B
↑ 87.91%
FY23Y/Y Change
Total Assets
824.3M
↓ 18.77%
Total Liabilities
1.2B
↑ 7.84%
Q3 FY22Q/Q Change
Total Assets
1.1B
↑ 39.42%
Total Liabilities
1.1B
↑ 65.37%
Q4 FY22Q/Q Change
Total Assets
1.0B
↓ 5.69%
Total Liabilities
1.1B
↑ 2.81%
Q1 FY23Q/Q Change
Total Assets
889.8M
↓ 12.31%
Total Liabilities
1.1B
↓ 0.34%
Q2 FY23Q/Q Change
Total Assets
779.9M
↓ 12.35%
Total Liabilities
1.1B
↓ 0.52%
Q3 FY23Q/Q Change
Total Assets
740.6M
↓ 5.04%
Total Liabilities
1.2B
↑ 5.97%
Q4 FY23Q/Q Change
Total Assets
824.3M
↑ 11.3%
Total Liabilities
1.2B
↑ 2.65%
FY18Y/Y Change
Operating Cash Flow
-101.2M
↓ 0.53%
Investing Cash Flow
5.1M
↓ 107.8%
Financing Cash Flow
13.1M
↓ 94.19%
FY19Y/Y Change
Operating Cash Flow
-90.9M
↓ 10.18%
Investing Cash Flow
-74.7M
↓ 1555.43%
Financing Cash Flow
159.8M
↑ 1116.81%
FY20Y/Y Change
Operating Cash Flow
8.9M
↓ 109.84%
Investing Cash Flow
-196.5M
↑ 163.05%
Financing Cash Flow
234.1M
↑ 46.52%
FY21Y/Y Change
Operating Cash Flow
-142.5M
↓ 1693.67%
Investing Cash Flow
-147.8M
↓ 24.8%
Financing Cash Flow
320.0M
↑ 36.67%
FY22Y/Y Change
Operating Cash Flow
-299.5M
↑ 110.15%
Investing Cash Flow
-262.1M
↑ 77.38%
Financing Cash Flow
516.2M
↑ 61.31%
Q3 FY22Q/Q Change
Operating Cash Flow
-84.0M
↓ 7.11%
Investing Cash Flow
-292.4M
↓ 547.96%
Financing Cash Flow
389.0M
↑ 11288.14%
Q4 FY22Q/Q Change
Operating Cash Flow
-98.2M
↑ 16.84%
Investing Cash Flow
29.2M
↓ 110.0%
Financing Cash Flow
29.9M
↓ 92.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-122.3M
↑ 24.54%
Investing Cash Flow
165.5M
↑ 465.82%
Financing Cash Flow
-7.2M
↓ 124.02%
Q2 FY23Q/Q Change
Operating Cash Flow
-121.8M
↓ 0.39%
Investing Cash Flow
82.1M
↓ 50.37%
Financing Cash Flow
5.5M
↓ 176.29%

Technicals Summary

Sell

Neutral

Buy

Cytokinetics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cytokinetics Inc
Cytokinetics Inc
-2.78%
105.03%
76.49%
147.57%
623.16%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cytokinetics Inc
Cytokinetics Inc
NA
NA
-0.42
-4.45
-5.72
-0.34
NA
-3.8
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cytokinetics Inc
Cytokinetics Inc
Buy
$6.9B
623.16%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • BlackRock Inc

    15.40%

  • FMR Inc

    12.44%

  • Vanguard Group Inc

    10.53%

  • Wellington Management Company LLP

    6.20%

  • State Street Corporation

    5.64%

  • T. Rowe Price Associates, Inc.

    3.10%

Corporate Announcements

  • Cytokinetics Inc Earnings

    Cytokinetics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Organization
Cytokinetics Inc
Employees
423
CEO
Mr. Robert I. Blum
Industry
Health Technology

Discover More

FAQs